Stock Ratings / Health Care / FULC / financials

VOGX (56) GLSI (41) RCKT (31) LRMR (50) ⌘ Pro Terminal →

Fulcrum Therapeutics Inc. (FULC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.77 +0.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.77

Fulcrum Therapeutics Inc. (FULC) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $288.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.77 (-0.09%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FULC)Realized 20D OHLCV Swing Band: ±3.9%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY FULC SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (28% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 48.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.77-3.2% Next Q

Q2 (-2Q)

Grade E$3.65+0.8% Next Q

Q3 (-1Q)

Grade E$3.68+2.4% Next Q

Current

Grade D-$3.77-7.4% Hist 90D α

Trajectory: E (32) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FULC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FULC currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.76) and Max Pain ($3.96) forces dealer call-delta covering toward $16.53.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FULC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FULC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How FULC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-2.1%	-$74.9M	-$60.4M	-44.2%
FY 2024	$4.00B	52%	-0.5%	-$9.7M	-$2.5M	-9.4%
FY 2023	$4.00B	52%	-2.8%	-$97.3M	-$91.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FULC)

✓Walkthrough of FULC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FULC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.12%▲ RESISTANCE BREAKOUT

2026-10-30O $3.74H $3.77L $3.68C $3.77VOL 933.2K

RES: $3.75SUP: $3.64SMA50: $3.76SMA200: $5.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FULC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FULC Butterfly Map → + Track FULC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FULC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FULC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FULC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FULC)

Health Care Rank #641 of 1016 ⚔️ VOGX vs FULC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FULC vs. VOGX, GLSI, RCKT, LRMR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Fulcrum Therapeutics Inc. (FULC) ranks #641 by composite RQD confidence (40/100, grade D-) and #524 by equity capitalization ($288.0M). Within this direct 5-issuer industry benchmark cohort, FULC leads on earnings valuation at N/A trailing P/E, while FULC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with FULC at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FULC ACTIVE Fulcrum Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.53%	$288.0M	Benchmark Subject
VOGX Vogenx Inc	D+	56/100	—	—	—	+5.29%	$295.9M	/vogx-vs-fulc →
GLSI Greenwich LifeSciences Inc.	D-	41/100	—	—	-35.0%	+3.77%	$278.9M	/glsi-vs-fulc →
RCKT Rocket Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-1.55%	$278.8M	/rckt-vs-fulc →
LRMR Larimar Therapeutics Inc.	D	50/100	—	—	-35.0%	+5.12%	$277.4M	/lrmr-vs-fulc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680581

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fulcrum Therapeutics Inc. (FULC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$74.9M, operating cash flow of -$60.1M, and free cash flow of -$60.4M (-2319.0% YoY). On the balance sheet, FULC closed FY2025 with $366.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$74.9M	-$60.1M	-$60.4M	$366.3M	—
FY2024 (FY)	2024-12-31	$0	-$9.7M	-$2.2M	-$2.5M	$260.7M	—
FY2023 (FY)	2023-12-31	$0	-$97.3M	-$91.0M	-$91.0M	—	—

3. FULC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FULC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Fulcrum Therapeutics Inc. (NASDAQ: FULC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.77 (+0.53% 1D, market cap $288.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FULC ranks #641 in composite RQD confidence.

How does FULC compare to VOGX and GLSI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FULC carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VOGX (Vogenx Inc) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $295.9M) and GLSI (Greenwich LifeSciences Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $278.9M). Among the 5-stock peer group, FULC leads on earnings multiple (N/A) while FULC leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FULC?

Per FULC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680581), Fulcrum Therapeutics Inc. generated $0 in revenue, -$74.9M in net income, and -$60.4M in free cash flow against $366.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FULC trading relative to its 50-day, 200-day, and 52-week technical levels?

FULC last traded at $3.77 (+0.53% on volume of 1,621,239 shares), positioning the stock +0.27% above its 50-day simple moving average ($3.76) and -35.67% below its 200-day simple moving average ($5.86). Across its 52-week range of $2.83 to $15.74, FULC sits at the 7.3% percentile with a 14-day RSI of 48.8 (NEUTRAL RANGE) and an implied next-earnings move of ±3.9% ($3.62 to $3.92).

FULC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Fulcrum Therapeutics Inc. (FULC)?

In FY 2025 (10-K), FULC converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: FULC RQD Cockpit FULC 12M Forecast FULC Earnings & Move FULC Dividends & DRIP FULC Insiders & 13F FULC Whale Options FULC Profit Sankey FULC News & Why